267 related articles for article (PubMed ID: 16885778)
1. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.
Manosuthi W; Chottanapand S; Thongyen S; Chaovavanich A; Sungkanuparph S
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):42-6. PubMed ID: 16885778
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.
Worodria W; Massinga-Loembe M; Mazakpwe D; Luzinda K; Menten J; Van Leth F; Mayanja-Kizza H; Kestens L; Mugerwa RD; Reiss P; Colebunders R;
J Acquir Immune Defic Syndr; 2011 Sep; 58(1):32-7. PubMed ID: 21654499
[TBL] [Abstract][Full Text] [Related]
3. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: an observational study.
Stockdale AJ; Nkuranga J; Török ME; Faragher B; Lalloo DG
Trop Med Int Health; 2013 Jul; 18(7):907-14. PubMed ID: 23590229
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death.
Kingkaew N; Sangtong B; Amnuaiphon W; Jongpaibulpatana J; Mankatittham W; Akksilp S; Sirinak C; Nateniyom S; Burapat C; Kittikraisak W; Monkongdee P; Varma JK
Int J Infect Dis; 2009 Nov; 13(6):722-9. PubMed ID: 19196530
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.
Nagu TJ; Aboud S; Mwiru R; Matee MI; Rao M; Fawzi WW; Zumla A; Maeurer MJ; Mugusi F
Int J Infect Dis; 2017 Mar; 56():39-44. PubMed ID: 28161460
[TBL] [Abstract][Full Text] [Related]
7. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy.
Girardi E; Palmieri F; Cingolani A; Ammassari A; Petrosillo N; Gillini L; Zinzi D; De Luca A; Antinori A; Ippolito G
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):326-31. PubMed ID: 11317073
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Mortality among Tuberculosis/HIV-Coinfected Persons in Southwest Ethiopia: A Case-Control Study.
Deribe K; Yami A; Deribew A; Mesfin N; Colebunders R; Van Geertruyden JP; Woldie M; Maja T
J Int Assoc Provid AIDS Care; 2015; 14(3):269-73. PubMed ID: 23966102
[TBL] [Abstract][Full Text] [Related]
9. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.
Uthman OA; Okwundu C; Gbenga K; Volmink J; Dowdy D; Zumla A; Nachega JB
Ann Intern Med; 2015 Jul; 163(1):32-9. PubMed ID: 26148280
[TBL] [Abstract][Full Text] [Related]
10. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy.
Liu E; Makubi A; Drain P; Spiegelman D; Sando D; Li N; Chalamilla G; Sudfeld CR; Hertzmark E; Fawzi WW
AIDS; 2015 Jul; 29(11):1391-9. PubMed ID: 26091295
[TBL] [Abstract][Full Text] [Related]
11. Low mortality rates at two years in HIV-infected individuals undergoing systematic tuberculosis testing with rapid assays at initiation of antiretroviral treatment in Mozambique.
Floridia M; Ciccacci F; Andreotti M; Mutemba E; Paulo A; Xavier M; Orlando S; Guidotti G; Giuliano M; Marazzi MC
Int J Infect Dis; 2020 Oct; 99():386-392. PubMed ID: 32791208
[TBL] [Abstract][Full Text] [Related]
12. Outcomes among HIV-1 infected individuals first starting antiretroviral therapy with concurrent active TB or other AIDS-defining disease.
Périssé AR; Smeaton L; Chen Y; La Rosa A; Walawander A; Nair A; Grinsztejn B; Santos B; Kanyama C; Hakim J; Nyirenda M; Kumarasamy N; Lalloo UG; Flanigan T; Campbell TB; Hughes MD;
PLoS One; 2013; 8(12):e83643. PubMed ID: 24391801
[TBL] [Abstract][Full Text] [Related]
13. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study.
Varma JK; Nateniyom S; Akksilp S; Mankatittham W; Sirinak C; Sattayawuthipong W; Burapat C; Kittikraisak W; Monkongdee P; Cain KP; Wells CD; Tappero JW
BMC Infect Dis; 2009 Apr; 9():42. PubMed ID: 19364398
[TBL] [Abstract][Full Text] [Related]
14. Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy.
Siika AM; Yiannoutsos CT; Wools-Kaloustian KK; Musick BS; Mwangi AW; Diero LO; Kimaiyo SN; Tierney WM; Carter JE
PLoS One; 2013; 8(1):e53022. PubMed ID: 23301015
[TBL] [Abstract][Full Text] [Related]
15. A mortality review of tuberculosis and HIV co-infected patients in Mahalapye, Botswana: Does cotrimoxazole preventive therapy and/or antiretroviral therapy protect against death?
Tshitenge S; Ogunbanjo GA; Citeya A
Afr J Prim Health Care Fam Med; 2018 Nov; 10(1):e1-e5. PubMed ID: 30456967
[TBL] [Abstract][Full Text] [Related]
16. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
17. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India.
Alvarez-Uria G; Pakam R; Midde M; Naik PK
J Int AIDS Soc; 2014; 17(1):19251. PubMed ID: 25499123
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand.
Sanguanwongse N; Cain KP; Suriya P; Nateniyom S; Yamada N; Wattanaamornkiat W; Sumnapan S; Sattayawuthipong W; Kaewsa-ard S; Ingkaseth S; Varma JK
J Acquir Immune Defic Syndr; 2008 Jun; 48(2):181-9. PubMed ID: 18520676
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm
Mutembo S; Mutanga JN; Musokotwane K; Alisheke L; Whalen CC
BMC Infect Dis; 2016 Oct; 16(1):572. PubMed ID: 27751168
[TBL] [Abstract][Full Text] [Related]
20. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
